Leverkusen, September 13, 2012 – Sandra E. Peterson, Chairman of the Executive Committee and Chief Executive Officer (CEO) of the subgroup Bayer CropScience, has asked for her contract, which runs until summer 2013, to be terminated effective November 30, 2012. The Supervisory Board of Bayer CropScience agreed to her request at a meeting on September 13, 2012.
“With her experience and commitment, Sandi has made significant contributions to the strong business performance of Bayer CropScience in the past two years,” said Dr. Marijn Dekkers, CEO of Bayer AG. “However, we accept her decision to continue her career back in her home country of the United States and wish her all the best for the future.” Born in 1959 in New York, N.Y., Peterson became CEO of Bayer CropScience on October 1, 2010. Before moving to Bayer CropScience, she was a member of the Executive Committee of Bayer HealthCare from May 2005, heading up the Medical Care Division from January 2009. Prior to that she was in charge of the Diabetes Care Division.
Peterson, who holds a B.A. in Government and a Master of Public Administration in Applied Economics, started her career as a management consultant at McKinsey & Company. She went on to hold various global executive positions with American home appliances manufacturer Whirlpool Corporation, subsequently being appointed Executive Vice President at foods company Nabisco. After that she became Senior Vice President of Merck-Medco's Health Businesses.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. As an inventor company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve the quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and acts as a socially and ethically responsible corporate citizen. In fiscal 2011, the Group employed about 112,000 people and had sales of €36.5 billion. Capital expenditures amounted to €1.7 billion, R&D expenses to €2.9 billion. For more information, go to www.bayer.com.
Find more information at www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.